This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bordi, C. Articles by Jensen, R. T. Search for Related Content PubMed PubMed Citation Articles by Bordi, C. Articles by Jensen, R. T.

The Antral Mucosa as a New Site for Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndromes¹

Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy (C.B., C.A., S.P., G.F.), University of Parma, I-43100 Parma, Italy; Department of Digestive Diseases, 2nd School of Medicine (V.D.C., G.D.F.), and Department of Cell Biotechnology and Hematology (V.D.C.), University La Sapienza, I-00161 Rome, Italy; and Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (F.G., R.T.J.), Bethesda, Maryland 20892

Address correspondence and requests for reprints to: Cesare Bordi, M.D., Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy, University of Parma, I-43100 Parma, Italy. E-mail: cesare.bordi{at}unipr.it

Carcinoid tumors were identified in the antro-pyloric mucosa of four patients with multiple endocrine neoplasia type 1 (MEN-1)/Zollinger-Ellison syndrome, accounting for 8.7% of 46 patients with this condition examined by endoscopy and histology. In contrast, no tumors were found in the antral biopsies from 124 cases of sporadic Zollinger-Ellison syndrome (P < 0.001), indicating a prominent role for the MEN-1 gene defects in tumor development. Immunohistochemically the tumors did not express the hormones produced by antral endocrine cells (gastrin, somatostatin, serotonin). In contrast, two of them were diffusely immunoreactive for the isoform 2 of the vesicular monoamine transporter (VMAT-2), a marker specific for the gastric nonantral enterochromaffin-like (ECL) cells. In one of these patients a second antral VMAT-2-positive carcinoid was seen 21 months after the first diagnosis. The other two antral carcinoids were unreactive for VMAT-2. Multiple ECL cell tumors were found in the gastric body-fundus mucosa of the two patients with VMAT-2-positive, but not in those with VMAT-2-negative, antral carcinoids. In one case, the former tumors were diagnosed 22 months after the detection of the antral tumor. We conclude that the antral mucosa is an additional tissue that may harbor endocrine tumors in MEN-1 syndrome. These tumors did not express the phenotype of normal antral endocrine cells and, in at least two cases, were identified as ectopic ECL cell carcinoids.